- Home
- LEXX vs NRXS Comparison
LEXX vs NRXS Comparison
Compare LEXX & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEXX
- NRXS
- Stock Information
- Founded
- LEXX 2004
- NRXS 2011
- Country
- LEXX Canada
- NRXS United States
- Employees
- LEXX N/A
- NRXS N/A
- Industry
- LEXX Biotechnology: Pharmaceutical Preparations
- NRXS
- Sector
- LEXX Health Care
- NRXS
- Exchange
- LEXX Nasdaq
- NRXS Nasdaq
- Market Cap
- LEXX 23.9M
- NRXS 25.8M
- IPO Year
- LEXX N/A
- NRXS 2023
- Fundamental
- Price
- LEXX $0.83
- NRXS $2.95
- Analyst Decision
- LEXX Strong Buy
- NRXS Strong Buy
- Analyst Count
- LEXX 1
- NRXS 1
- Target Price
- LEXX $4.00
- NRXS $7.00
- AVG Volume (30 Days)
- LEXX 1.4M
- NRXS 74.0K
- Earning Date
- LEXX 11-25-2025
- NRXS 11-11-2025
- Dividend Yield
- LEXX N/A
- NRXS N/A
- EPS Growth
- LEXX N/A
- NRXS N/A
- EPS
- LEXX N/A
- NRXS N/A
- Revenue
- LEXX $615,923.00
- NRXS $3,217,531.00
- Revenue This Year
- LEXX $46.98
- NRXS $62.14
- Revenue Next Year
- LEXX $17.26
- NRXS $131.87
- P/E Ratio
- LEXX N/A
- NRXS N/A
- Revenue Growth
- LEXX 49.85
- NRXS 41.93
- 52 Week Low
- LEXX $0.77
- NRXS $1.33
- 52 Week High
- LEXX $3.05
- NRXS $6.20
- Technical
- Relative Strength Index (RSI)
- LEXX 41.83
- NRXS 50.65
- Support Level
- LEXX $0.83
- NRXS $2.94
- Resistance Level
- LEXX $0.92
- NRXS $3.44
- Average True Range (ATR)
- LEXX 0.07
- NRXS 0.18
- MACD
- LEXX -0.02
- NRXS -0.01
- Stochastic Oscillator
- LEXX 12.97
- NRXS 16.95
About LEXX Lexaria Bioscience Corp.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).